Zacks: Analysts Expect China Biologic Products, Inc. (CBPO) to Announce $1.32 Earnings Per Share
Analysts predict that China Biologic Products, Inc. (NASDAQ:CBPO) will report earnings of $1.32 per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $1.22 in the same quarter last year, which suggests a positive year-over-year growth rate of 8.2%. The business is expected to issue its next earnings results on Wednesday, November 1st.
On average, analysts expect that China Biologic Products will report full-year earnings of $5.04 per share for the current year, with EPS estimates ranging from $5.02 to $5.06. For the next financial year, analysts forecast that the business will report earnings of $5.90 per share, with EPS estimates ranging from $5.78 to $6.02. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover China Biologic Products.
China Biologic Products (NASDAQ:CBPO) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business had revenue of $89.28 million for the quarter, compared to the consensus estimate of $97.33 million. During the same period last year, the business earned $1.26 earnings per share. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year.
Several analysts recently issued reports on the stock. Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of China Biologic Products in a research report on Tuesday, May 30th. They set a “neutral” rating on the stock. Finally, BidaskClub lowered shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $132.00.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/22/zacks-analysts-expect-china-biologic-products-inc-cbpo-to-announce-1-32-earnings-per-share.html.
Hedge funds have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. purchased a new stake in China Biologic Products during the first quarter valued at about $156,000. Eqis Capital Management Inc. increased its position in shares of China Biologic Products by 51.3% in the first quarter. Eqis Capital Management Inc. now owns 3,220 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 1,092 shares during the last quarter. Nomura Holdings Inc. bought a new position in shares of China Biologic Products during the first quarter valued at approximately $463,000. Gateway Advisory LLC bought a new position in shares of China Biologic Products during the first quarter valued at approximately $480,000. Finally, Jennison Associates LLC increased its position in shares of China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 44 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.
China Biologic Products (CBPO) traded up 0.46% during midday trading on Tuesday, reaching $91.66. The company had a trading volume of 135,369 shares. The stock’s 50 day moving average price is $98.75 and its 200-day moving average price is $106.37. The firm has a market capitalization of $2.50 billion, a P/E ratio of 23.86 and a beta of 1.70. China Biologic Products has a one year low of $88.25 and a one year high of $126.47.
China Biologic Products Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.